Abstract 11204: Long-term Effects of Sarpogrelate, a Selective Serotonin Receptor Antagonist, in Diabetic Patients with Stable Angina and Chronic Kidney Disease
Background: Diabetes mellitus (DM) and Chronic Kidney Disease (CKD) are known as a major risk factor for cardiovascular disease (CVD). Sarpogrelate, a selective serotonin blocker, is known to have not only the inhibitory effects of platelet aggregation and vasoconstriction, but also the improvement of albuminuria. This study was designed to investigate long-term effects of sarpogrelate in diabetic patients with stable angina and chronic kidney disease (CKD).
Methods: After the standard medical therapy, seventy nine type 2 diabetic patients with stable angina and CKD (stage 3 or 4) were randomized to receive sarpogrelate (sarpogrelate group, n=42) or not to receive sarpogrelate (control group, n=37). We measured flow-mediated dilatation (FMD) of brachial artery and pulse wave velocity (PWV), and assessed exercise tolerance and renal function (estimated glomerular filtration rate, eGFR). Measurements were performed at baseline, and then at every one year after the treatments. The primary outcome was major adverse cardiovascular events, or hospitalization for revascularization during a follow-up period 7.7 to 8.0 years (median, 7.9 years).
Results: FMD, PWV, exercise tolerance and eGFR were much better in the sarpogrelate group during a follow-up period. The 7.9-year cumulative primary-event rates were 14.3% in the sarpogrelate group and 35.1% in the control group (p=0.039 by log-lank test).
Conclusion: Sarpogrelate, a serotonin blocker, not only improves vascular function (FMD, PWV), exercise tolerance, and eGFR, but also improves long-term outcome in diabetic patients with stable angina and CKD.
- © 2011 by American Heart Association, Inc.